Industry Trend Analysis - Discriminatory Patent Law Will Encourage Adaptive Strategies For Multinational Drugmakers - MAY 2017


BMI View : Indonesia ' s regulatory environment will remain highly challenging for innovative pharmaceutical firms. The country's designation as a 'Priority Watch List' country in PhRMA's 2017 submission highlights a discriminatory intellectual property environment and non-transparent approval policies as ongoing concerns for multinational drugmakers. Despite the challenges involved, the Indonesian pharmaceutical market continues to hold significant potential as the largest in South East Asia, typified by Indonesia ' s status as a high-risk high-reward pharmaceutical market for innovative drugmakers.

Amendments to Indonesia's Patent Law will weaken the level of intellectual property protection accorded to innovative pharmaceutical firms in the country. In line with our expectations, ( See 'Amendments To Patent Law To Pose Challenges For Innovative Drugmakers', Aug ust 12 2016), Indonesia has maintained its position on the 'Priority Watch List' in the Pharmaceutical Research and Manufacturers of America (PhRMA)'s Special 301 submission for 2017 - notably only India and Thailand share this status in the Asia Pacific region. Key issues highlighted in the submission are consistent with previous years, with many of the shortcomings previously raised still unaddressed.

Intellectual Property Protection In Indonesia To Weaken

This article is part of our Asia coverage. To access this article subscribe now or sign up for free trial